کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
9162084 | 1173456 | 2005 | 12 صفحه PDF | دانلود رایگان |
عنوان انگلیسی مقاله ISI
Emerging Strategies in the Prevention of Venous Thromboembolism in Hospitalized Medical Patients
دانلود مقاله + سفارش ترجمه
دانلود مقاله ISI انگلیسی
رایگان برای ایرانیان
کلمات کلیدی
Hospitalized medical patientsVTEPF4LMWHUFHArtemis - آرتمیسControlled trials - آزمایشات کنترل شدهPulmonary embolism - آمبولی ریهMyocardial infarction - آنفارکتوس میوکاردHIT - اصابتIMPROVE - بهتر کردنutilization - بهره برداریVenous thromboembolism - ترومبوآمبولی وریدیDVT - ترومبوز سیاهرگی عمقیDeep venous thrombosis - ترومبوز ورید عمیقHeparin-induced thrombocytopenia - ترومبوسیتوپنی ناشی از هپارینthromboprophylaxis - ترومبوفیلیکسیسPrevent - جلوگیری کردنPlatelet factor 4 - عامل فلوتر 4confidence interval - فاصله اطمینانFondaparinux - فونداپارینوکسodds ratio - نسبت شانس هاunfractionated heparin - هپارین غیر اشباع شدهlow-molecular-weight heparin - هپارین کم وزن مولکولی
موضوعات مرتبط
علوم پزشکی و سلامت
پزشکی و دندانپزشکی
کاردیولوژی و پزشکی قلب و عروق
پیش نمایش صفحه اول مقاله
![عکس صفحه اول مقاله: Emerging Strategies in the Prevention of Venous Thromboembolism in Hospitalized Medical Patients Emerging Strategies in the Prevention of Venous Thromboembolism in Hospitalized Medical Patients](/preview/png/9162084.png)
چکیده انگلیسی
Venous thromboembolism (VTE) remains a significant cause of morbidity and mortality in hospitalized patients with acute medical illness. The high prevalence of VTE in this patient population, its clinically silent nature, and associated morbidity and mortality indicate that prophylactic therapy is appropriate in those determined to be at increased risk. Unfractionated heparin (UFH) and low-molecular-weight heparin (LMWH) have been shown to reduce the incidence of VTE and are the primary therapies used for prophylaxis in these patients. Although both UFH and LMWH have received grade 1A recommendations for the prevention of VTE in at-risk medical patients in the 2004 American College of Chest Physicians consensus conference statements, LMWH has advantages over UFH in its once-daily dosing scheme, reduced incidence of major and minor bleeding events, and reduced incidence of heparin-induced thrombocytopenia. Fondaparinux is a novel antithrombotic agent characterized by specificity for factor Xa and a lack of platelet interaction. A recent clinical trial in hospitalized patients with acute medical illness found that fondaparinux significantly reduced the incidence of both VTE and fatal pulmonary embolism compared with placebo, without increased major bleeding. Despite the availability of effective thromboprophylactic therapies, VTE prophylaxis continues to be underutilized in hospitalized medical patients
ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Chest - Volume 128, Issue 2, August 2005, Pages 958-969
Journal: Chest - Volume 128, Issue 2, August 2005, Pages 958-969
نویسندگان
Spyropoulos MD, FCCP,